• 1. Site-selective Suzuki–Miyaura coupling of heteroaryl halides – understanding the trends for pharmaceutically important classes
  Joshua Almond-Thynne,David C. Blakemore,David C. Pryde,Alan C. Spivey Chem. Sci. 2017 8 40

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Quinazolines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Benzodiazines Quinazolines

Introduction to 6-Bromo-2,4-dichloroquinazoline (CAS No. 102393-82-8)

6-Bromo-2,4-dichloroquinazoline, with the chemical formula C?H?BrCl?N?, is a significant heterocyclic compound that has garnered considerable attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the quinazoline class, a structural motif widely recognized for its biological activity and pharmacological potential. The presence of bromine and chlorine substituents at specific positions on the quinazoline ring enhances its reactivity, making it a valuable intermediate in the synthesis of various bioactive molecules.

The chemical structure of 6-Bromo-2,4-dichloroquinazoline features a six-membered aromatic ring fused with a pyrimidine-like moiety. The bromine atom at the 6-position and the chlorine atoms at the 2- and 4-positions contribute to its unique electronic properties, which are exploited in organic synthesis and medicinal chemistry. This compound is particularly noteworthy due to its role as a precursor in the development of novel therapeutic agents targeting diverse diseases.

In recent years, 6-Bromo-2,4-dichloroquinazoline has been extensively studied for its applications in drug discovery. Its structural framework is conducive to further functionalization, allowing chemists to explore modifications that enhance its pharmacological properties. One of the most compelling aspects of this compound is its potential as a scaffold for kinase inhibitors, particularly those targeting tyrosine kinases involved in cancer progression.

Current research highlights the use of 6-Bromo-2,4-dichloroquinazoline in the synthesis of small-molecule inhibitors that exhibit potent antitumor activity. For instance, derivatives of this compound have shown promising results in preclinical studies by interfering with key signaling pathways that drive cell proliferation and survival. The bromine and chlorine substituents serve as handles for further chemical manipulation, enabling the development of highly specific inhibitors with improved selectivity and reduced toxicity.

Another area where 6-Bromo-2,4-dichloroquinazoline has made significant contributions is in the field of antiviral research. Quinazoline derivatives are known for their ability to inhibit viral enzymes essential for replication. By incorporating bromine and chlorine atoms into the quinazoline core, researchers have been able to enhance the binding affinity and stability of these compounds towards viral targets. This has led to the discovery of novel antiviral agents that show efficacy against a range of pathogens.

The synthesis of 6-Bromo-2,4-dichloroquinazoline typically involves multi-step organic reactions starting from readily available precursors. The introduction of bromine and chlorine atoms is achieved through halogenation reactions, which can be carefully controlled to ensure regioselectivity. Advanced synthetic methodologies, such as cross-coupling reactions and palladium-catalyzed transformations, have been employed to construct the desired quinazoline framework efficiently.

From a medicinal chemistry perspective, 6-Bromo-2,4-dichloroquinazoline represents an excellent example of how structural modifications can lead to significant improvements in drug efficacy. The presence of electron-withdrawing groups at specific positions on the ring enhances the compound's ability to interact with biological targets. This has spurred interest in developing libraries of quinazoline derivatives for high-throughput screening (HTS) campaigns aimed at identifying new therapeutic candidates.

The pharmacokinetic properties of 6-Bromo-2,4-dichloroquinazoline and its derivatives are also subjects of intense investigation. Researchers are focusing on optimizing solubility, bioavailability, and metabolic stability to ensure that these compounds can progress into clinical development. Techniques such as computational modeling and structure-activity relationship (SAR) studies are being utilized to guide these efforts.

In conclusion,6-Bromo-2,4-dichloroquinazoline (CAS No. 102393-82-8) is a versatile and highly valuable compound in pharmaceutical research. Its unique structural features make it an ideal candidate for further derivatization into bioactive molecules with therapeutic potential. Ongoing studies continue to uncover new applications for this compound, reinforcing its importance in drug discovery efforts worldwide.

• 125096-72-2(8-Bromo-4-chloroquinazoline)
• 573675-55-5(7-Bromo-4-chloroquinazoline)
• 20028-68-6(2,4,6-Trichloroquinazoline)
• 6625-94-1(2,4,7-Trichloroquinazoline)
• 331647-05-3(8-Bromo-2,4-dichloroquinazoline)
• 351426-04-5(6-Bromo-4-chloro-2-methylquinazoline)
• 38267-96-8(6-Bromo-4-chloroquinazoline)
• 607-68-1(2,4-Dichloroquinazoline)
• 885524-31-2(QUINAZOLINE, 6,7-DIBROMO-4-CHLORO-)
• 2148-38-1(5-Bromo-4-chloro-quinazoline)